Evidence map›Paper›PMID 34319512›Full record

ArticleAging clinical and experimental research2021

The role of collaborative, multistakeholder partnerships in reshaping the health management of patients with noncommunicable diseases during and after the COVID-19 pandemic.

Alessandro Monaco, Amaia Casteig Blanco, Mark Cobain, Elisio Costa, Nick Guldemond, Christine Hancock, Graziano Onder, Sergio Pecorelli, Mitchell Silva, Jos Tournoy and 9 more

Open access · hybridAbstract read
In one paragraph

Article in Aging clinical and experimental research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Mapping the Public Health Landscape in Greece: Governance, Stakeholders, Data Systems, and Policy Frameworks.International journal of environmental research and public health · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 12 institutions in 8 countries.

Alessandro MonacoHEC, Rue de la Libération 1, 78350, Paris, Jouy-en-Josas, France. alessandro.monaco@hec.edu.ORCID http://orcid.org/0000-0002-9941-7003
Amaia Casteig BlancoGrupo OAT Therapeutic Adherence Observatory, Observatorio de La Salud S.L, Madrid, Spain.
Mark CobainYounger Lives Ltd, London, UK.
Elisio CostaUCIBIO/REQUIMTE Applied Molecular Biosciences Unit, Faculty of Pharmacy and Competences Center On Active and Healthy Ageing (Porto4Ageing), University of Porto, Porto, Portugal.
Nick GuldemondLeiden University Medical Center LUMC-NL, Leiden, The Netherlands.
Christine HancockC3 Collaborating for Health, London, UK.
Graziano OnderItalian National Institute of Health, Istituto Superiore Di Sanità, Rome, Italy.
Sergio PecorelliUniversity of Brescia, Brescia, Italy.
Mitchell SilvaEsperity, Brussels, Belgium.
Jos TournoyKU, Leuven, Belgium.
Caterina TrevisanGeriatric Unit, Department of Medicine, University of Padua, Padua, Italy.
Mariano VottaActive Citizenship Network, Cittadinanzattiva APS, Rome, Italy.
John YfantopoulosNational and Kapodistrian University of Athens, Athens, Greece.
Stecy YghemonosEurocarers, Brussels, Belgium.
Vincent ClayUpjohn (Pfizer), Brussels, Belgium.
Franco Mondello MalvestitiViatris, Rome, Italy.
Karine De SchaetzenViatris, Brussels, Belgium.
Georgia SykaraViatris, Athens, Greece.
Shaantanu DondeViatris, London, UK.
Centre for Science, Society and Citizenship · ITEuropean Society of Intensive Care Medicine · BEHEC Paris · FRImperial College London · GBIstituto Superiore di Sanità · ITKU Leuven · BENational and Kapodistrian University of Athens · GRPfizer (Belgium) · BESechenov University · RUUniversidade do Porto · PTUniversity of Brescia · ITUniversity of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPolicies to combat the COVID-19 pandemic have disrupted the screening, diagnosis, treatment, and monitoring of noncommunicable (NCD) patients while affecting NCD prevention and risk factor control.

aimsTo discuss how the first wave of the COVID-19 pandemic affected the health management of NCD patients, identify which aspects should be carried forward into future NCD management, and propose collaborative efforts among public-private institutions to effectively shape NCD care models.

methodsThe NCD Partnership, a collaboration between Upjohn and the European Innovation Partnership on Active and Healthy Ageing, held a virtual Advisory Board in July 2020 with multiple stakeholders; healthcare professionals (HCPs), policymakers, researchers, patient and informal carer advocacy groups, patient empowerment organizations, and industry experts.

resultsThe Advisory Board identified barriers to NCD care during the COVID-19 pandemic in four areas: lack of NCD management guidelines; disruption to integrated care and shift from hospital-based NCD care to more community and primary level care; infodemics and a lack of reliable health information for patients and HCPs on how to manage NCDs; lack of availability, training, standardization, and regulation of digital health tools.

conclusionsMultistakeholder partnerships can promote swift changes to NCD prevention and patient care. Intra- and inter-communication between all stakeholders should be facilitated involving all players in the development of clinical guidelines and digital health tools, health and social care restructuring, and patient support in the short-, medium- and long-term future. A comprehensive response to NCDs should be delivered to improve patient outcomes by providing strategic, scientific, and economic support.

Indexed as

COVID-19Noncommunicable DiseasesCaregiversHumansPandemicsSARS-CoV-2AdherenceAgeingCOVID-19HealthcareInformal carersNCDNoncommunicable diseasesPatient advocacyPatient empowermentPublic–private partnershipsSARS-CoV-2

Identifiers

PMID34319512
PMCPMC8316535
OpenAlexW3183633242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.